You searched for "Cancer"
Introduction to prostate cryotherapy
Introduction Cryotherapy was first described by Dr James Arnott in 1850 where he used crushed ice and salt to get temperatures as low as -24oC, in the treatment of cervical and breast tumours [1]. The literature on prostatic cryotherapy dates...Neuroendocrine bladder tumour
A 75-year-old male with a history of prostate adenocarcinoma (T3b/T4 N1 M1b, Gleason 4+3) on Zoladex® and enzalutamide, presented with visible haematuria. His prostate specific antigen (PSA) had decreased from 43.6ug/L in December 2022 to 0.02ug/L. He also had a...Drinks Reception: Latest data from the GALEAS Bladder NHS Real World Evaluation at BAUS (British Association of Urological Surgeons) 2025
Join the team behind GALEAS Bladder, the urinary biomarker test delivering results equivalent to a cystoscopy for the detection and monitoring of bladder cancer, along with special guests, to find out how GALEAS Bladder has performed in the NHS Real World Evaluation. 6 - 7pm, drinks and presentations 7pm onwards, drinks, networking and food
Radium-223 treatment outcomes after multiple lines of mCRPC therapy in clinical practice: implication of pre-treatment spinal epidural disease
There are a number of treatments now available to patients with metastatic castrate-resistant prostate cancer (mCRPC). However, the optimal timing and order in which they are given is less clear. Radium-223 was FDA-approved for mCRPC patients with symptomatic bone metastases...
Predicting bone scan positivity in non-metastatic CRPC
There is evidence that suggests that early treatment with chemotherapy, immunotherapy or hormone therapy leads to a better response in patients with asymptomatic metastatic castrate resistant prostate cancer (CRPC). This study aimed to predict bone scan positivity in patients with...Upper urinary tract urothelial cell carcinoma
Case 1 A 64-year-old man presents to the haematuria clinic with visible haematuria, on a background of a 40 pack-year smoking history and family history of bowel cancer in his sister at the age of 48. A CT was performed...
Importance of PSA variation – an analysis of PLCO trial data
This study looks specifically at the group of patients in the intervention arm of the Prostate, Lung, Colorectal, and Ovarian Cancer Screening trial (PLCO), to investigate variations in prostate specific antigen (PSA) level. They have specifically included only patients who...HIV / AIDS – implications for the urologist
“It’s no fun to have HIV even though it’s viewed as a chronic, controllable disease. It means being wedded to the health system.” - Philip Berger, Associate Professor in the Department of Family and Community Medicine, Toronto, Canada; and leading...PREDICT Prostate – individualised, evidence-based estimates of survival and treatment benefit
Earlier this year ‘PREDICT Prostate’ was launched online alongside a high-profile publication in PLOS Medicine. The prognostic model and decision-aid has been designed to inform treatment decision-making among men newly diagnosed with non-metastatic prostate cancer. David Thurtle and Vincent Gnanapragasam...In conversation with Tim O’Brien
We were delighted to catch up with Tim O’Brien, President of BAUS, about his career highlights and plans for the association. Can you tell us a little bit about what led you into the field of urology and the highlights...
